RESEARCH ARTICLE

No need for secondary *Pneumocystis jirovecii* pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL

Andrew Atkinson1,§,* Jose M. Miro2,*, Amanda Mocroft3, Peter Reiss4,5, Ole Kirk6, Philippe Morlat7, Jade Ghosn8,9, Christoph Stephan10, Cristina Mussini11, Anastasia Antoniadou12, Katja Doerholt13, Enrico Girardi14, Stéphane De Wit15, David Kraus1,16, Marcel Zwahlen17, Hansjakob Furrer1 and on behalf of the Opportunistic Infections Working Group of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCOORD

§Corresponding author: Andrew Atkinson, Department of Infectious Diseases, Bern University Hospital, University of Bern, 3010 Bern, Switzerland. Tel: +41 31 632 69 68. (andrew.atkinson@insel.ch)

*These authors have equivalent merits.

Abstract

**Introduction:** Since the beginning of the HIV epidemic in resource-rich countries, *Pneumocystis jirovecii* pneumonia (PjP) is one of the most frequent opportunistic AIDS-defining infections. The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) has shown that primary *Pneumocystis jirovecii* Pneumonia (PjP) prophylaxis can be safely withdrawn in patients with CD4 counts of 100 to 200 cells/µL if plasma HIV-RNA is suppressed on combination antiretroviral therapy. Whether this holds true for secondary prophylaxis is not known, and this has proved difficult to determine due to the much lower population at risk.

**Methods:** We estimated the incidence of secondary PjP by including patient data collected from 1998 to 2015 from the COHERE cohort collaboration according to time-updated CD4 counts, HIV-RNA and use of PjP prophylaxis in persons >16 years of age. We fitted a Poisson generalized additive model in which the smoothed effect of CD4 was modelled by a restricted cubic spline, and HIV-RNA was stratified as low (<400), medium (400 to 10,000) or high (>10,000 copies/mL).

**Results:** There were 373 recurrences of PjP during 74,295 person-years (py) in 10,476 patients. The PjP incidence in the different plasma HIV-RNA strata differed significantly and was lowest in the low stratum. For patients off prophylaxis with CD4 counts between 100 and 200 cells/µL and HIV-RNA below 400 copies/mL, the incidence of recurrent PjP was 3.9 (95% CI: 2.0 to 5.8) per 1000 py, not significantly different from patients on prophylaxis in the same stratum (1.9, 95% CI: 0.1 to 3.7).

**Conclusions:** HIV viraemia importantly affects the risk of recurrent PjP. In virologically suppressed patients on ART with CD4 counts of 100 to 200/µL, the incidence of PjP off prophylaxis is below 10/1000 py. Secondary PjP prophylaxis may be safely withheld in such patients. While European guidelines recommend discontinuing secondary PjP prophylaxis only if CD4 counts rise above 200 cells/µL, the latest US Guidelines consider secondary prophylaxis discontinuation even in patients with a CD4 count above 100 cells/µL and suppressed viral load. Our results strengthen and support this US recommendation.

**Keywords:** opportunistic infections; *Pneumocystis jirovecii* pneumonia; prophylaxis

Additional information may be found under the Supporting Information tab for this article.

Received 16 December 2020; Accepted 15 April 2021

Copyright © 2021 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

1 | INTRODUCTION

Since the beginning of the HIV epidemic in resource-rich countries, *Pneumocystis jirovecii* pneumonia (PjP) is one of the most frequent opportunistic AIDS-defining infections [1]. PjP occurs predominantly in people living with HIV (PLWH) with marked immunodeficiency with CD4 positive lymphocytes in peripheral blood (CD4 count) of less than 200 cells/µL or less than 14 % of total lymphocytes [2]. In the era before potent antiretroviral therapy (ART) this led to the recommendation of
providing life-long primary chemoprophylaxis against PjP in all PLWH with a CD4 count below this threshold. While PjP incidence decreased substantially in the era of ART it still occurs in patients presenting late during their HIV infection, in those lost to care, those non-adherent or failing ART [3,4]. The risk of recurrence of PjP after successful treatment of a first episode was shown to be particularly high [5,6]. This may in part be due to genetic susceptibility for PjP [7]. Therefore, secondary prophylaxis or maintenance therapy was recommended for all patients having experienced PjP [8].

With the advent of potent ART, several studies have shown that primary and secondary PjP prophylaxis can be safely discontinued once the CD4 count rises to above 200 cells/µL [9-14].

Within the large Collaboration of Observational HIV Epidemiological Research in Europe (COHERE), we have previously shown that HIV viraemia as measured by plasma HIV-RNA is an additional important risk factor for PjP, independent of the CD4 count. Primary PjP prophylaxis may be safely withheld in patients on successful ART, with CD4 counts between 100 and 200 cells/µL [15]. In patients in this CD4 count stratum, with plasma HIV RNA below 400 copies/mL and off prophylaxis the incidence of primary PjP was 12 (95% CI 2 to 45) events per 1000 person-years (py). A more recent analysis pointed towards safety of discontinuing prophylaxis even in all patients that achieve undetectable plasma HIV-RNA levels [16]. Similar findings were reported by smaller cohorts [17-19], a randomized trial [20] and in two systematic reviews [21,22]. While the combined results of discontinuation of primary prophylaxis in the patients of interest indicated an incidence with a 95% confidence interval upper boundary below 10/1000 py, the data on discontinuation of secondary prophylaxis remained inconclusive [19,20,22]. Nevertheless, in recent years many physicians stopped prescribing PjP prophylaxis in patients on successful ART, even with low CD4 counts [23].

We evaluated the risk of secondary PjP in patients on and off prophylaxis at different levels of CD4 count and plasma HIV-RNA based on a large database with long follow-up.

2 | METHODS

2.1 | Setting

COHERE in EuroCoord was a collaborative group of adult, pediatric, and mother/child HIV cohorts across Europe. The collaboration allows comparisons across age categories and provides a mechanism to rapidly compile datasets to address novel research questions that cannot be studied adequately in individual cohorts (www.eurocoord.net, www.cohere.org) [24]. Data were extracted from the 2015 merger of COHERE that included 23 European cohorts, with information on patient characteristics (age, sex and transmission category), use of ART (type of regimen and dates of start and discontinuation), CD4 cell counts and plasma HIV-RNA over time and their dates, AIDS-defining conditions and indicator variables for drop-out or death.

2.2 | Analysis

The results are reported as median and interquartile ranges for the quantitative variables, whereas those for qualitative variables are expressed as absolute frequency along with the associated percentage. The Kruskal-Wallis test was used for continuous and Fisher’s exact test for categorical variables.

We calculated the incidence rate (events per 1000py) stratified by current use of PjP-prophylaxis and by plasma HIV-RNA levels (<400, 400 to 10,000 copies/mL and >10,000 copies/mL). Poisson regression with a log link function was used to analyze associations between the incidence of PjP diagnosis, dependent on the use of secondary prophylaxis. Follow-up started at the first visit at which the inclusion criteria were met (16 years of age or over, began follow-up in their cohort after 1998, and a previous PjP diagnosis). As potential risk factors, we included gender (reference male), age, probable mode of HIV transmission (with categories men having sex with men (MSM) (reference), heterosexual and “other”), current HIV RNA level, current CD4 count and the contributing cohort. We fitted restricted cubic splines to model the smoothed effect of changing CD4 count over time using general additive Poisson models, calculated with sandwich-type standard errors to adjust for patients contributing multiple periods of follow-up time. These spline models enable the visualization of the incidence trajectory for continuous CD4 counts in a given viral load stratum. We varied the number of knots used for the splines to investigate the goodness of fit and to avoid overfitting.

The level of missingness for baseline and time-varying variables was considered negligible (<10%), and therefore we did not resort to using formal missing data methods in the analysis. Last observation carried forward was used to impute missing post-baseline CD4 and RNA measurements. All analyses were carried out with R version 3.2.4, using the function “gam” in package “mgcv” to fit the general additive models [25,26]. Throughout we considered a level of 0.05 as statistically significant.

2.3 | Ethical approval

Ethical approval was applied for and granted for the research from the appropriate body in the host country of the cohort contributing the data to COHERE.

2.4 | Patient consent

Patient consent was obtained by each of the cohorts as defined locally as a pre-requisite for sharing information with the COHERE collaboration.

3 | RESULTS

There were 10,476 patients with PjP and a follow-up time of 74,295 py at risk for secondary PjP. The overall incidence was 5.0 (4.5, 5.6) per 1000 py for 373 secondary PjP events occurring in the period 1998 to 2015. Patient characteristics for the total population and for those who did or did not develop secondary PjP are shown in Table 1. Those who developed secondary PjP were more likely to be female and infected by intravenous drug use. They were also younger and had lower CD4 counts and higher plasma HIV RNA at baseline.
Table 1. Characteristics of patients at baseline for those with and without a secondary PjP diagnosis during follow-up

<table>
<thead>
<tr>
<th></th>
<th>Overall</th>
<th>No secondary PjP diagnosis</th>
<th>Secondary PjP diagnosis</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>10476</td>
<td>10103</td>
<td>373</td>
<td>-</td>
</tr>
<tr>
<td>Female (%)</td>
<td>2082 (19.9%)</td>
<td>1987 (19.7%)</td>
<td>95 (25.5%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age at baseline (median [IQR])</td>
<td>40 [35, 47]</td>
<td>40 [35, 48]</td>
<td>38 [34, 44]</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HIV transmission mode (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MSM</td>
<td>4144 (39.6)</td>
<td>4020 (39.8%)</td>
<td>124 (33.2%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Heterosexual</td>
<td>3544 (33.8)</td>
<td>3429 (33.9%)</td>
<td>115 (30.8%)</td>
<td></td>
</tr>
<tr>
<td>IDU</td>
<td>1390 (13.3)</td>
<td>1309 (13.0%)</td>
<td>81 (21.7%)</td>
<td></td>
</tr>
<tr>
<td>Other, unknown</td>
<td>394 (3.4)</td>
<td>373 (3.7)</td>
<td>21 (5.6%)</td>
<td></td>
</tr>
<tr>
<td>Missing</td>
<td>1004 (9.6)</td>
<td>972 (9.6%)</td>
<td>32 (8.6%)</td>
<td></td>
</tr>
<tr>
<td>CD4 count/µL (median [IQR])</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>80 [24, 220]</td>
<td>80 [25, 221]</td>
<td>64 [22, 190]</td>
<td>0.07</td>
</tr>
<tr>
<td>At final follow-up visit</td>
<td>–</td>
<td>415 [220, 628]</td>
<td>100 [29, 270]</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Plasma HIV-RNA/µL (median [IQR])</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>71882 [500, 308000]</td>
<td>70000 [500, 306000]</td>
<td>101000 [11500, 351064]</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>At final follow-up visit</td>
<td>–</td>
<td>49 [22, 79]</td>
<td>24400 [155, 210000]</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Follow-up time in years per patient (median [IQR])</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>–</td>
<td>6.5 [2.7, 11.5]</td>
<td>1.9 [0.6, 3.9]</td>
<td>0.001</td>
<td></td>
</tr>
<tr>
<td>Percentage of follow-up on ART (median [IQR])</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>–</td>
<td>96% [65%, 100%]</td>
<td>99% [64%, 100%]</td>
<td>0.1</td>
<td></td>
</tr>
</tbody>
</table>

ART, antiretroviral therapy; IDU, intravenous drug use; IQR, interquartile range; MSM, men who have sex with men; PjP, pneumocystis jirovecii pneumonia.

Figure 1 and Table 2 depict the incidence in patients at risk of secondary PjP. The incidence of recurrent PjP in the low HIV-RNA stratum with CD4 counts 100 to 200 cells/µL for patients off secondary prophylaxis was estimated to be 3.9 (95% CI: 2.0 to 5.8) events per 1000 py (Figure 1a), as compared to 1.9 (95% CI 0.1 to 3.7; p = 0.1) on prophylaxis. In patients with suppressed viral load, we could exclude an incidence of more than 10/1000py for those with current CD4 counts of at least 95 cells/µL at a 95% confidence level.

Even in patients off prophylaxis in the CD4 count stratum below 100 cells/µL with suppressed viral load, the PjP incidence was low at 8.9/1000 py (95% CI 3.3 to 12.9). Figure 1b presents the estimates from the fitted Poisson model for a reference patient (35-year old, male MSM) with a cubic spline smoother for the CD4 count, stratified by level of viral suppression (low, medium and high). According to this model, the upper boundary of the 95% confidence interval of PjP incidence increased to more than 20/1000 years in patients with very low CD4 counts (Figure 1b, left panel). As depicted in Figure 1b left panel, we found an incidence of <10/1000 py in patients with CD4 counts higher than 95 cells/µL at a 95% confidence level. There was a marginally significant higher risk for patients with transmission risk IDU compared to MSM as reference (RR 1.3, 95% CI 1.0 to 1.80 p = 0.05). The supplementary Figure presents the estimates from the fitted Poisson model for a 35-year old, male IDU reference patient.

Viral replication was strongly associated with higher PjP incidence at every current CD4 count stratum (Table 2 and Figure 1) both for patients on and off prophylaxis. In fact, in patients with plasma HIV RNA above 10,000 c/mL we could not exclude an incidence of less than 10/1000 py for patients with current CD4 counts of more than 200 cells/µL in patients off or on prophylaxis (Figure 1b). The supplementary Table shows the estimates of incidence rate ratios from the fitted model for several risk factors.

4 | DISCUSSION

HIV viraemia is an independent major risk factor for secondary PjP, as we have previously demonstrated to be the case for primary PjP [15]. For patients on ART with suppressed viral load, the risk for secondary PjP is below 10/1000 py once their CD4 count has risen to above 95 cells/µL.

However, the risk for secondary PjP remains above 10/1000 py, even with CD4 counts of >200 cells/µL, in case of replicating HIV with a plasma HIV-RNA level above 10,000 copies/µL.

Secondary PjP prophylaxis can therefore be safely discontinued in asymptomatic patients on ART with plasma viral loads of <400 copies/µL, a CD4 count above 100 cells/µL, and no other risk factors for PjP, such as additional immunosuppression or chronic lung disease. This would allow stopping or withholding secondary prophylaxis in most Western European patients with current CD4 counts between 100 and 200 cells/µL since viral suppression is achieved in more than 80% in patients on ART [27].

HIV replication has been shown to be an important, and CD4 count an independent, factor interfering with immunocompetence. It has also been associated with a higher risk of tuberculosis [28], and with a lower response to vaccination against yellow fever [29], influenza [30] and hepatitis B [31].

Taking an upper 95% confidence limit for the incidence of PjP to be less than 10/1000 py as a threshold to safely withholding prophylaxis is somewhat arbitrary. However, in many of the pivotal studies defining the safety of discontinuation of PjP prophylaxis, the upper 95% confidence level of incidence was in this range, or even slightly higher [9-15]. Showing the smoothed effect of current CD4 count on incidence of PjP by fitting the spline models (Figure 1b) allows the treating physicians to define the safety margin themselves, based on our
Figure 1. Incidence of secondary Pneumocystis Pneumonia (PiP). (a) Stratified by CD4 count (cells/µL) and plasma HIV-RNA (copies/mL) levels for those on or off PiP prophylaxis; point estimates indicated by circles with 95% confidence intervals as vertical error bars. (b) Stratified plasma HIV-RNA levels from those off (left panel) and on (right panel) PiP prophylaxis. Plasma HIV-RNA levels: High >10,000, Medium 400-10,000, Low <400 copies/mL. From the fitted Poisson general additive model for a 35 year old, male, MSM with 95% confidence intervals shown shaded in the respective colour. HIV, human immunodeficiency virus; HIV-RNA, human immunodeficiency virus (HIV) Ribonucleic acid; MSM, men who have sex with men; PiP, Pneumocystis jirovecii pneumonia; Py, person years; Py, person years; RNA, Ribonucleic acid; VL, Viral load
Table 2. Incidence of secondary Pneumocystis Pneumonia (PJP) stratified by CD4 count (cells/µL) and plasma HIV-RNA (copies/mL) and being on or off prophylaxis

<table>
<thead>
<tr>
<th>CD4 strata</th>
<th>RNA strata</th>
<th>Secondary PJP prophylaxis</th>
<th>Number of events</th>
<th>Follow-up time (1000 person years)</th>
<th>Incidence [95% CI]</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;100</td>
<td>&lt;400</td>
<td>No</td>
<td>11</td>
<td>1353.9</td>
<td>8.1 [3.3, 12.9]</td>
</tr>
<tr>
<td>&lt;100</td>
<td>&lt;400</td>
<td>Yes</td>
<td>7</td>
<td>887.0</td>
<td>7.9 [2.0, 13.7]</td>
</tr>
<tr>
<td>&lt;100</td>
<td>400 to 10,000</td>
<td>No</td>
<td>10</td>
<td>545.6</td>
<td>18.3 [7.0, 29.7]</td>
</tr>
<tr>
<td>&lt;100</td>
<td>400 to 10,000</td>
<td>Yes</td>
<td>5</td>
<td>369.2</td>
<td>13.5 [1.7, 25.4]</td>
</tr>
<tr>
<td>&lt;100</td>
<td>&gt;10,000</td>
<td>No</td>
<td>114</td>
<td>1920.4</td>
<td>59.3 [48.5, 70.3]</td>
</tr>
<tr>
<td>&lt;100</td>
<td>&gt;10,000</td>
<td>Yes</td>
<td>40</td>
<td>1098.5</td>
<td>36.4 [26.0, 49.6]</td>
</tr>
<tr>
<td>101 to 200</td>
<td>&lt;400</td>
<td>No</td>
<td>16</td>
<td>4085.6</td>
<td>3.9 [2.0, 5.8]</td>
</tr>
<tr>
<td>101 to 200</td>
<td>&lt;400</td>
<td>Yes</td>
<td>4</td>
<td>2096.7</td>
<td>1.9 [0.1, 3.7]</td>
</tr>
<tr>
<td>101 to 200</td>
<td>400 to 10,000</td>
<td>No</td>
<td>8</td>
<td>852.9</td>
<td>9.4 [2.9, 15.8]</td>
</tr>
<tr>
<td>101 to 200</td>
<td>400 to 10,000</td>
<td>Yes</td>
<td>3</td>
<td>499.4</td>
<td>6.0 [0.1, 12.8]</td>
</tr>
<tr>
<td>101 to 200</td>
<td>&gt;10,000</td>
<td>No</td>
<td>18</td>
<td>814.0</td>
<td>22.1 [11.9, 32.3]</td>
</tr>
<tr>
<td>101 to 200</td>
<td>&gt;10,000</td>
<td>Yes</td>
<td>7</td>
<td>448.3</td>
<td>15.6 [4.1, 27.2]</td>
</tr>
<tr>
<td>&gt;200</td>
<td>&lt;400</td>
<td>No</td>
<td>73</td>
<td>4877.6</td>
<td>1.5 [1.2, 1.8]</td>
</tr>
<tr>
<td>&gt;200</td>
<td>&lt;400</td>
<td>Yes</td>
<td>10</td>
<td>3728.5</td>
<td>2.7 [1.0, 4.3]</td>
</tr>
<tr>
<td>&gt;200</td>
<td>400 to 10,000</td>
<td>No</td>
<td>14</td>
<td>3707.6</td>
<td>3.8 [1.8, 5.8]</td>
</tr>
<tr>
<td>&gt;200</td>
<td>400 to 10,000</td>
<td>Yes</td>
<td>4</td>
<td>810.5</td>
<td>4.9 [0.1, 10.0]</td>
</tr>
<tr>
<td>&gt;200</td>
<td>&gt;10,000</td>
<td>No</td>
<td>20</td>
<td>1936.6</td>
<td>10.3 [5.8, 14.9]</td>
</tr>
<tr>
<td>&gt;200</td>
<td>&gt;10,000</td>
<td>Yes</td>
<td>9</td>
<td>363.9</td>
<td>24.7 [8.6, 40.9]</td>
</tr>
</tbody>
</table>

CI, confidence interval; HIV, human immunodeficiency viruses; PJP, pneumocystis pneumonia, RNA, ribonucleic acid.
Lower age and IDU as HIV-transmission risk were both associated with a somewhat higher risk of secondary PJP, which, as pointed out in other studies, might be an indication of lower ART adherence. In addition, co-infections such as active hepatitis C could further compromise immune-competence in IDUs.

Our recommendation may not apply to all geographical settings. Co-trimoxazole prophylaxis has been shown to be associated with lower morbidity and mortality in patients with higher CD4 cell counts in Sub-Saharan Africa, mainly due to its effectiveness in preventing infections other than PJP [34,35]. Furthermore, our findings result from averaging data from many countries, and therefore individual settings may require a slightly more conservative approach.

5 | CONCLUSIONS

In conclusion, in the absence of other risk factors, secondary PJP prophylaxis can be safely discontinued, or withheld, in patients who have both a CD4 count above 100 cells/µL and a suppressed viral load on ART. Conversely, it may be warranted to prescribe prophylaxis for viraemic patients with a viral load greater than 10,000 copies/mL, even those having a CD4 count above 200 cells/µL.

AUTHORS’ AFFILIATIONS

1Department of Infectious Diseases, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland; 2Infectious Diseases Service, Hospital Clinic – IDIBAPS, University of Barcelona, Barcelona, Spain; 3Centre for Clinical Research, Epidemiology, Modeling and Evaluation (CREME), Institute for Global Health, UCL, London, UK; 4Department of Global Health, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands; 5Amsterdam Institute for Global Health and Development, and HIV Monitoring Foundation, Amsterdam, The Netherlands; 6CHIP, Department of Infectious Diseases, Rotterdam Institute for Global Health and Development, and HIV Monitoring Foundation, The Netherlands; and the Augustinus Foundation, Bern, Switzerland.

CONCLUSIONS

Our recommendation may not apply to all geographical settings. Co-trimoxazole prophylaxis has been shown to be associated with lower morbidity and mortality in patients with higher CD4 cell counts in Sub-Saharan Africa, mainly due to its effectiveness in preventing infections other than PJP [34,35]. Furthermore, our findings result from averaging data from many countries, and therefore individual settings may require a slightly more conservative approach.

AUTHORS’ AFFILIATIONS

1Department of Infectious Diseases, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland; 2Infectious Diseases Service, Hospital Clinic – IDIBAPS, University of Barcelona, Barcelona, Spain; 3Centre for Clinical Research, Epidemiology, Modeling and Evaluation (CREME), Institute for Global Health, UCL, London, UK; 4Department of Global Health, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands; 5Amsterdam Institute for Global Health and Development, and HIV Monitoring Foundation, Amsterdam, The Netherlands; 6CHIP, Department of Infectious Diseases, Rotterdam Institute for Global Health and Development, and HIV Monitoring Foundation, The Netherlands; and the Augustinus Foundation, Bern, Switzerland.

CONCLUSIONS

In conclusion, in the absence of other risk factors, secondary PJP prophylaxis can be safely discontinued, or withheld, in patients who have both a CD4 count above 100 cells/µL and a suppressed viral load on ART. Conversely, it may be warranted to prescribe prophylaxis for viraemic patients with a viral load greater than 10,000 copies/mL, even those having a CD4 count above 200 cells/µL.

AUTHORS’ AFFILIATIONS

1Department of Infectious Diseases, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland; 2Infectious Diseases Service, Hospital Clinic – IDIBAPS, University of Barcelona, Barcelona, Spain; 3Centre for Clinical Research, Epidemiology, Modeling and Evaluation (CREME), Institute for Global Health, UCL, London, UK; 4Department of Global Health, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands; 5Amsterdam Institute for Global Health and Development, and HIV Monitoring Foundation, Amsterdam, The Netherlands; 6CHIP, Department of Infectious Diseases, Rotterdam Institute for Global Health and Development, and HIV Monitoring Foundation, The Netherlands; and the Augustinus Foundation, Bern, Switzerland.

CONCLUSIONS

In conclusion, in the absence of other risk factors, secondary PJP prophylaxis can be safely discontinued, or withheld, in patients who have both a CD4 count above 100 cells/µL and a suppressed viral load on ART. Conversely, it may be warranted to prescribe prophylaxis for viraemic patients with a viral load greater than 10,000 copies/mL, even those having a CD4 count above 200 cells/µL.

AUTHORS’ AFFILIATIONS

1Department of Infectious Diseases, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland; 2Infectious Diseases Service, Hospital Clinic – IDIBAPS, University of Barcelona, Barcelona, Spain; 3Centre for Clinical Research, Epidemiology, Modeling and Evaluation (CREME), Institute for Global Health, UCL, London, UK; 4Department of Global Health, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands; 5Amsterdam Institute for Global Health and Development, and HIV Monitoring Foundation, Amsterdam, The Netherlands; 6CHIP, Department of Infectious Diseases, Rotterdam Institute for Global Health and Development, and HIV Monitoring Foundation, The Netherlands; and the Augustinus Foundation, Bern, Switzerland.

CONCLUSIONS

In conclusion, in the absence of other risk factors, secondary PJP prophylaxis can be safely discontinued, or withheld, in patients who have both a CD4 count above 100 cells/µL and a suppressed viral load on ART. Conversely, it may be warranted to prescribe prophylaxis for viraemic patients with a viral load greater than 10,000 copies/mL, even those having a CD4 count above 200 cells/µL.

AUTHORS’ AFFILIATIONS

1Department of Infectious Diseases, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland; 2Infectious Diseases Service, Hospital Clinic – IDIBAPS, University of Barcelona, Barcelona, Spain; 3Centre for Clinical Research, Epidemiology, Modeling and Evaluation (CREME), Institute for Global Health, UCL, London, UK; 4Department of Global Health, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands; 5Amsterdam Institute for Global Health and Development, and HIV Monitoring Foundation, Amsterdam, The Netherlands; 6CHIP, Department of Infectious Diseases, Rotterdam Institute for Global Health and Development, and HIV Monitoring Foundation, The Netherlands; and the Augustinus Foundation, Bern, Switzerland.
REFERENCES


SUPPORTING INFORMATION

Additional information may be found under the Supporting Information tab for this article.

Table S1. Estimates of incidence rate ratios (IRR) for secondary Pneumocystis jiroveci pneumonia (PjP) from the fitted general additive model with a cubic spline smoother for CD4 count. In

personal 80:20 research grant from Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, during 2017 to 2021, and has received consulting honoraria and/or research grants from AbbVie, Angelini, Contrafact, Cubist, Genentech, Gilead Sciences, Jansen, Medtronic, MSD, Novartis, Pfizer, and ViV Healthcare, outside of the submitted work. H Furrer reports grants to the institution from ViV, Gilead, MSD, Abbvie and Sandoz, outside the submitted work. All other authors report no competing interests.
addition, there was a highly significant association of PjP with lower CD4 counts ($p < 0.001$). CI, Confidence interval; IDU, intravenous drug use; MSM, men who have sex with men

**Figure S1.** Incidence of secondary Pneumocystis Pneumonia (PjP) stratified plasma HIV-RNA levels from those off (left panel) and on (right panel) PjP prophylaxis. Plasma HIV-RNA levels: High $>10,000$, Medium $400-10,000$, Low $<400$ copies/mL. From the fitted Poisson general additive model for a 35-year-old male IDU patient with 95% confidence intervals shown shaded in the respective colour.